Lexicon Pharmaceuticals
LXRX
136 hedge funds and large institutions have $1.64B invested in Lexicon Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 48 increasing their positions, 43 reducing their positions, and 23 closing their positions.
12% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 43
10% more call options, than puts
Call options by funds: $5.09M | Put options by funds: $4.61M
7% more capital invested
Capital invested by funds: $1.53B → $1.64B (+$107M)
3.13% more ownership
Funds ownership: 106.32% → 109.45% (+3.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 23
6% less funds holding
Funds holding: 145 → 136 (-9)
Top Buyers
| 1 |
BlackRock
New York
|
+$71.8M |
| 2 |
CLM
ClearBridge LLC (Maryland)
Baltimore,
Maryland
|
+$10.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.68M |
| 4 |
HCM
Highbridge Capital Management
New York
|
+$8.08M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$7.64M |
Top Sellers
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.98M |
| 2 |
Charles Schwab
San Francisco,
California
|
-$1.81M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$1.67M |
| 4 |
Citigroup
New York
|
-$1.62M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$1.22M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NIT
151
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
| – | -$196K | -14,202 | Closed |
|
|
SCM
152
Sterling Capital Management
Charlotte,
North Carolina
| – | -$195K | -14,112 | Closed |
|
|
SCM
153
Stevens Capital Management
Radnor,
Pennsylvania
| – | -$154K | -11,142 | Closed |
|
|
PPA
154
Parametric Portfolio Associates
Seattle,
Washington
| – | -$150K | -10,840 | Closed |
|
155
HSBC Holdings
London,
United Kingdom
| – | -$144K | -10,365 | Closed |
|
|
AIM
156
Acrospire Investment Management
Chicago,
Illinois
| – | -$137K | -9,931 | Closed |
|
|
TRCT
157
Tower Research Capital (TRC)
New York
| – | -$24K | -1,740 | Closed |
|
|
QI
158
QS Investors
New York
| – | -$6K | -436 | Closed |
|
|
KLI
159
Kelman-Lazarov Inc
Memphis,
Tennessee
| – | -$2.81K | -203 | Closed |
|
LXRX Hedge Fund Activity: Q1 2017 in Review
136 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q1 2017, worth a combined $1.64B — up 7% from $1.53B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of LXRX and 21 opened new positions — a net loss of 2 holders — while 43 trimmed existing stakes and 48 added.
The largest buyer was BlackRock, adding an estimated $71.8M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $3.98M sold.
- 136 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q1 2017, down from 145 in Q4 2016.
- Funds reported $1.64B of Lexicon Pharmaceuticals stock for Q1 2017, up 7% quarter-over-quarter.
- 21 funds opened new Lexicon Pharmaceuticals positions in Q1 2017 and 23 closed out, a net change of -2 holders.
- The largest Lexicon Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $71.8M added.
- The largest Lexicon Pharmaceuticals seller in Q1 2017 was Susquehanna International Group, an estimated $3.98M sold.
Based on aggregated 13F filings for Q1 2017.